secwatch.observer — SEC 8-K summary
======================================

Issuer:     Propanc Biopharma, Inc. (PPCB)
CIK:        0001517681
Form:       8-K
Filed at:   2026-10-29T21:00:33+00:00
Accession:  0001493152-26-049298
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Propanc Biopharma receives Nasdaq delisting notice; no 180-day cure period due to prior reverse split
--------------------------------------------------------------------------------

- Nasdaq notice dated Oct 23, 2026: PPCB closed below $1.00 minimum bid for the 30 consecutive business days before Oct 21, 2026.
- Company is ineligible for the standard 180-day compliance period under Rule 5810(c)(3)(A)(iv) because it effected a reverse stock split in the prior year.
- Delisting set for Nov 2, 2026 unless Propanc appeals to a Nasdaq Hearings Panel by Oct 30, 2026; the company says it intends to appeal.
- Propanc claims it has cured the bid price deficiency since receiving the notice; appeal would stay delisting pending the Panel's decision.
- Company cites risks: reduced liquidity, fewer investors, loss of registration statement access, and impaired employee equity incentives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517681/000149315226049298/0001493152-26-049298-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517681/000149315226049298/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-049298

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer